What is the price of Zolgensma (onasemnogene abeparvovec) and are there other brands available?

Zolgensma Pricing and Brand Availability

Zolgensma (onasemnogene abeparvovec-xioi) is the only brand name available for onasemnogene abeparvovec, and it carries a list price of $2.125 million for the single-dose treatment. 1

Brand Name Information

• Onasemnogene abeparvovec is marketed exclusively under the brand name Zolgensma by Novartis (formerly AveXis Inc). 1, 2, 3
• No alternative brand names or generic versions of onasemnogene abeparvovec currently exist. 2, 3
• The full designation is onasemnogene abeparvovec-xioi, with Zolgensma being the commercial name used in clinical practice. 2, 4

Pricing Details

List Price

• The manufacturer's list price for Zolgensma is $2.125 million for the one-time intravenous infusion. 5
• This represents one of the highest-priced medications globally, though it is administered as a single dose rather than requiring ongoing treatment. 3, 4

Cost-Effectiveness Context

• When compared to nusinersen (Spinraza), which requires multiple intrathecal administrations over a lifetime, Zolgensma's one-time cost may be more cost-effective long-term, with estimated lifetime costs of $3.93 million for Zolgensma versus $4.60 million for nusinersen. 5
• At the list price of $2.125 million, cost-effectiveness analyses suggest Zolgensma is dominant (both more effective and less costly) compared to nusinersen, and costs approximately $161,648 per quality-adjusted life year (QALY) gained compared to best supportive care. 5

Important Pricing Considerations

• Actual net prices paid by insurers are typically lower than the list price due to confidential rebates and negotiations, though specific negotiated prices are not publicly disclosed. 5
• Patient out-of-pocket costs vary substantially depending on insurance coverage, with most costs covered under medical benefits (Medicare Part B or commercial medical insurance) rather than pharmacy benefits. 1
• Families should contact Novartis directly for patient assistance programs and current pricing information specific to their insurance situation. 6, 3

Access and Reimbursement Challenges

• Drug access is hindered by the extremely high cost, payer reimbursement complexities, and the need for prior authorization in most insurance plans. 3
• The one-time payment model creates unique challenges for healthcare systems and insurers compared to traditional ongoing therapies. 3, 5